Prof. Dr. Margret Schottelius

Wissenschaftliche Mitarbeiterin

Margret Schottelius studierte Chemie an den Universitäten Konstanz und Rutgers sowie der ETH Zürich. Ihre Diplomarbeit fertigte sie am Laboratoire de Pharmacochimie Moléculaire der Université Louis Pasteur in Strasbourg. Es folgten Promotion und Habilitation im Fachbereich Nuklearmedizin und Radiopharmazie an der TU München. Ihr Forschungsinteresse richtet sich auf die Optimierung der Pharmakokinetik von peptidischen Rezeptorliganden sowie Entwicklung und Evaluierung peptischer Liganden und Proteine für Krebsdiagnostik und Therapie.


Forschung

  • Optimierung der Pharmakokinetik von peptidischen Rezeptorliganden durch Glykosylierung sowie Übertragung und Adaptierung des Konzepts an diverse Markierungsstrategien (Dissertation und Habilitation)
  • Entwicklung und Evaluierung neuer peptidischer Liganden für krebsrelevante GPCRs

Lehre

  • Vorlesung „Radiopharmazie für Mediziner“
  • Vorlesung „Radiopharmazie“
  • Grundlagenvorlesung Radiopharmazie
  • Vorlesung „Spezielle Aspekte der Radiopharmazie“

Publikationen

  • Schottelius M, Osl T, Poschenrieder A, Hoffmann F, Beykan S, Hänscheid H, Franke K, et al., [177Lu]pentixather: comprehensive preclinical evaluation of a first CXCR4-directed endoradiotherapeutic agent. Theranostics. 2017;7(9):2350-2362.
  • Hyafil F*, Pelisek J, Laitinen I, Schottelius M, Mohring M, Döring Y, van der Vorst E P C, Kallmayer M, Steiger K, Poschenrieder A, Notni J, Fischer J, Baumgartner C, Rischpler C, Nekolla S G, Weber C, Eckstein H-H, Wester H-J, Schwaiger M. Imaging the cytokine receptor CXCR4 in atherosclerotic plaques with the radiotracer 68Ga-pentixafor for positron emission tomography. J. Nucl. Med. 2016
  • Poschenrieder A, Schottelius M, Osl T, Schwaiger M, Wester H-J, [64Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model, EJNMMI Radiopharmacy and Chemistry. 2017;2:2.
  • Production of clinical radiopharmaceuticals: general pharmaceutical and radioanalytical aspects; Schmidt, A., Schottelius, M., Herz, M. et al. J Radioanal Nucl Chem (2016). doi:10.1007/s10967-016-5125-6
  • Poschenrieder A, Schottelius M, Schwaiger M, Wester HJ. Preclinical evaluation of [68Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo - a comparison to [68Ga]pentixafor. EJNMMI Res. 2016, 6(1), 70.
  • Poschenrieder A, Schottelius M, Schwaiger M, Kessler H, Wester HJ. The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity. EJNMMI Res. 2016, 6(1), 36.
  • Hyafil F, Pelisek J, Laitinen I, Schottelius M, Mohring M, Döring Y, Van der Vorst E, Kallmayer M, Steiger K, Poschenrieder A, Notni J, Fischer J, Baumgartner C, Rischpler C, Nekolla S, Weber C, Eckstein HH, Wester HJ, Schwaiger M. Imaging the cytokine receptor CXCR4 in atherosclerotic plaques with the radiotracer 68Ga-pentixafor for positron emission tomography. J. Nucl. Med. 2016 Oct 27. pii: jnumed.116.179663.
  • Maurer T, Schwamborn K, Schottelius M, Wester HJ, Schwaiger M, Gschwend JE, Eiber M. PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. Clin. Genitourin. Cancer. 2016, 14(5), e549-e552.
  • Robu S, Schottelius M, Eiber M, Maurer T, Gschwend J, Schwaiger M, Wester HJ. Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer. J. Nucl. Med. 2016, Sep 15. pii: jnumed.116.178939.
  • Rauscher I, Maurer T, Souvatzoglou M, Beer AJ, Vag T, Wirtz M, Weirich G, Wester HJ, Gschwend JE, Schwaiger M, Schottelius M, Eiber M. Intrapatient Comparison of 111In-PSMA I&T SPECT/CT and Hybrid 68Ga-HBED-CC PSMA PET in Patients With Early Recurrent Prostate Cancer. Clin. Nucl. Med. 2016, 41(9), e397-402.
  • Herhaus P, Habringer S, Philipp-Abbrederis K, Vag T, Gerngross C, Schottelius M, Slotta-Huspenina J, Steiger K, Altmann T, Weißer T, Steidle S, Schick M, Jacobs L, Slawska J, Müller-Thomas C, Verbeek M, Subklewe M, Peschel C, Wester HJ, Schwaiger M, Götze K, Keller U. Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia. Haematologica. 2016, 101(8), 932-940.
  • Heck MM, Retz M, D'Alessandria C, Rauscher I, Scheidhauer K, Maurer T, Storz E, Janssen F, Schottelius M, Wester HJ, Gschwend JE, Schwaiger M, Tauber R, Eiber M. Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. J. Urol. 2016, 196(2), 382-391.
  • Baum RP, Kulkarni HR, Schuchardt C, Singh A, Wirtz M, Wiessalla S, Schottelius M, Mueller D, Klette I, Wester HJ. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J. Nucl. Med. 2016, 57(7), 1006-1013.
  • Poschenrieder A, Osl T, Schottelius M, Hoffmann F, Wirtz M, Schwaiger M, Wester HJ. First 18F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo. Tomography. 2016, 2 (2), 85-93.
  • Maurer T, Schwamborn K, Schottelius M, Wester HJ, Schwaiger M, Gschwend JE, Eiber M. PSMA Theranostics Using PET and Subsequent Radioguided Surgery in Recurrent Prostate Cancer. Clin. Genitourin. Cancer. 2016, pii:S1558-7673(16)30146-X.
  • Rischpler C, Nekolla SG, Kossmann H, Dirschinger RJ, Schottelius M, Hyafil F, Wester HJ, Laugwitz KL, Schwaiger M. Upregulated myocardial CXCR4-expression after myocardial infarction assessed by simultaneous GA-68 pentixafor PET/MRI. J. Nucl. Cardiol. 2016, 23(1), 131-133.
  • Herrmann K, Schottelius M, Lapa C, Osl T, Poschenrieder A, Haenscheid H, Lueckerath K, Schreder M, Bluemel C, Knott M, Keller U, Schirbel A, Samnick S, Lassmann M, Kropf S, Buck A, Einsele H, Wester HJ, Knop S. First-in-man experience of CXCR4-directed endoradiotherapy with 177Lu- and 90Y-labelled pentixather in advanced stage multiple myeloma with extensive intra- and extramedullary disease. J. Nucl. Med. 2016, 57(2), 248-251.
  • Chatalic KL, Heskamp S, Konijnenberg M, Molkenboer-Kuenen JD, Franssen GM, Clahsen-van Groningen MC, Schottelius M, Wester HJ, van Weerden WM, Boerman OC, de Jong M. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics. 2016, 6(6), 849-861.
  • Schottelius M, Wirtz M, Eiber M, Maurer T, Wester HJ. [111In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery. EJNMMI Res. 2015, 5(1), 68.
  • Schottelius M , Konrad M, Osl T, Poschenrieder A, Wester HJ. An optimized strategy for the mild and efficient solution phase iodination of tyrosine residues in bioactive peptides. Tetrahedron Lett. 2015, 56(47), 6602-6605.
  • Maurer T, Weirich G, Schottelius M, Weineisen M, Frisch B, Okur A, Kübler H, Thalgott M, Navab N, Schwaiger M, Wester HJ, Gschwend J, Eiber M. Prostate-specific Membrane Antigen-radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer. Eur. Urol. 2015, 68(3), 530-534.
  • Weineisen M, Schottelius M, Simecek J, Baum RP, Yildiz A, Beykan S, Kulkarni HR, Lassmann M, Klette I, Eiber M, Schwaiger M, Wester HJ. Ga-68- and Lu-177-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J. Nucl. Med. 2015, 56(8), 1169-1176.
  • Herrmann K, Bluemel C, Weineisen M, Schottelius M, Wester HJ, Czernin J, Eberlein U, Beykan S, Lapa C, Riedmiller H, Krebs M, Kropf S, Schirbel A, Buck AK, Lassmann M. Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy. J. Nucl. Med. 2015, 56(6), 855-861.
  • Schottelius M, Simecek J, Hoffmann F, Willibald M, Schwaiger M, Wester HJ. Twins in spirit - episode I: comparative preclinical evaluation of [Ga-68]DOTATATE and [Ga-68]HA-DOTATATE. EJNMMI Res. 2015, 5, 22.
  • Philipp-Abbrederis K, Herrmann K, Knop S, Schottelius M, Eiber M, Lückerath K, Pietschmann E, Habringer S, Gerngross C, Franke K, Rudelius M, Schirbel A, Lapa C, Schwamborn K, Steidle S, Hartmann E, Rosenwald A, Kropf S, Beer AJ, Peschel C, Einsele H, Buck AK, Schwaiger M, Götze K, Wester HJ, Keller U. In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol. Med. 2015, 7(4), 477-487.
  • Herrmann K, Lapa C, Wester HJ, Schottelius M, Schiepers C, Eberlein U, Bluemel C, Keller U, Knop S, Kropf S, Schirbel A, Buck AK, Lassmann M. Biodistribution and Radiation Dosimetry for the Chemokine Receptor CXCR4-Targeting Probe Ga-68-Pentixafor. J. Nucl. Med. 2015, 56(3), 410-416. Volume: 56
  • Wester HJ, Keller U, Schottelius M, Beer A, Philipp-Abbrederis K, Hoffmann F, Simecek J, Gerngross C, Lassmann M, Herrmann K, Pellegata N, Rudelius M, Kessler H, Schwaiger M. Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging. Theranostics 2015, 5(6), 618-630.
  • Weineisen M, Simecek J, Schottelius M, Schwaiger M, Wester HJ. Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer. EJNMMI Res 2014, 4, 63.
  • Neubauer S, Rechenmacher F, Brimioulle R, Di Leva FS, Bochen A, Sobahi TR, Schottelius M, Novellino E, Mas-Moruno C, Marinelli L, Kessler H. Pharmacophoric Modifications Lead to Superpotent αvβ3 Integrin Ligands with Suppressed α5β1 Activity. J. Med Chem. 2014, 57(8), 3410-3417.
  • Hartmann H , Freudenberg R, Oehme L, Zöphel K, Schottelius M, Wester HJ, Wunderlich G, Kotzerke J, Brogsitter C. Dosimetric measurements of Ga-68-High Affinity DOTATATE Twins in spirit - part III. Nuklearmedizin – Nuclear Medicine 2014, 53(5), 211-216.
  • Brogsitter C, Zöphel K, Hartmann H, Schottelius M, Wester HJ, Kotzerke J. Twins in spirit part II: DOTATATE and high-affinity DOTATATE-the clinical experience. Eur. J. Nucl. Med. Mol. Imaging 2014, 41(6), 1158-1165.
  • Brogsitter C, Schottelius M, Zophel K, Kotzerke J, Wester HJ. Twins in spirit: DOTATATE and high-affinity DOTATATE. Eur. J. Nucl. Med. Mol. Imaging 2013, 40(11), 1789.
  • Shen Y, Schottelius M, Zelenka K, De Simone M, Pohle K, Kessler H, Wester HJ, Schmutz P, Alberto R. Orthogonally Protected Artificial Amino Acid as Tripod Ligand for Automated Peptide Synthesis and Labeling with [99mTc(OH2)3(CO)3]+. Bioconj. Chem. 2013, 24(1), 26-35.
  • Demmer O, Frank AO, Hagn F, Schottelius M, Marinelli L, Cosconati S, Brack-Werner R, Kremb S, Wester HJ, Kessler H. A conformationally frozen peptoid boosts CXCR4 affinity and anti-HIV activity. Angew. Chemie, Int. Ed. 2012, 51(32), 8110-8113.
  • Gourni E, Demmer O, Schottelius M, D'Alessandria C, Schulz S, Dijkgraaf I, Schumacher U, Schwaiger M, Kessler H, Wester HJ. PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J. Nucl. Med. 2011, 52(11), 1803-1810.
  • Schottelius M, Wester HJ. Molecular imaging targeting peptide receptors (Review). Methods 2009, 48(2), 161-177.
  • Hultsch C, Schottelius M, Auernheimer J, Alke A, Wester HJ. 18F-Fluoroglucosylation of peptides, exemplified on cyclo(RGDfK). Eur. J. Nucl. Med. Mol. Imaging 2009, 36(9), 1469-1474.
  • Schottelius M, Laufer B, Kessler H, Wester HJ. Ligands for mapping v3-integrin expression in vivo (Review). Acc. Chem. Res. 2009, 42 (7), 969-980.
  • Schottelius M, Berger S, Poethko T, Schwaiger M, Wester HJ. Development of novel 68Ga- and 18F-labeled GnRH-I analogues with high GnRHR-targeting efficiency. Bioconjug. Chem. 2008, 19(6), 1256-1268.
  • Demmer O, Dijkgraaf I, Schottelius M, Wester HJ, Kessler H. Introduction of functional groups into peptides via N-alkylation. Org. Lett. 2008, 10(10), 2015-2018.
  • Schlapschy M, Theobald I, Mack H, Schottelius M, Wester HJ, Skerra A. Fusion of a recombinant antibody fragment with a homo-amino-acid polymer: effects on biophysical properties and prolonged plasma half-life. PEDS 2007, 20(6), 273-284.
  • Knör S, Modlinger A, Poethko T, Schottelius M, Wester HJ. Synthesis of novel 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) derivatives for chemoselective attachment to unprotected polyfunctionalized compounds. Chem. Eur. J. 2007, 13(21), 6082-6090.
  • Auernheimer J, Haubner R, Schottelius M, Wester HJ, Kessler H. Radio-Analytical Determination of the Coating Efficiency of Cyclic RGD Peptides. Helv. Chim. Acta 2006, 89 (5), 833-840.
  • Meisetschlager G, Poethko T, Stahl A, Wolf I, Scheidhauer K, Schottelius M, Herz M, Wester HJ, Schwaiger M. Gluc-Lys([18F]FP)-TOCA PET in Patients with SSTR-Positive Tumors: Biodistribution and Diagnostic Evaluation Compared with [111In]DTPA-Octreotide. J. Nucl. Med. 2006, 47(4), 566-573.
  • Bruus-Jensen K, Poethko T, Schottelius M, Hauser A, Schwaiger M, Wester HJ. Chemoselective hydrazone formation between HYNIC-functionalized peptides and 18F-fluorinated aldehydes. Nucl. Med. Biol. 2006, 33(2), 173-183.
  • Vaidyanathan G, Affleck DJ, Schottelius M, Wester H, Friedman HS, Zalutsky MR. Synthesis and Evaluation of Glycosylated Octreotate Analogues Labeled with Radioiodine and 211At via a Tin Precursor. Bioconjug. Chem. 2006, 17(1), 195-203.
  • Stahl A, Meisetschlager G, Schottelius M, Bruus-Jensen K, Wolf I, Scheidhauer K, Schwaiger M. [123I]Mtr-TOCA, a radioiodinated and carbohydrated analogue of octreotide: scintigraphic comparison with [111In]octreotide. Eur J Nucl Med Mol Imaging 2006, 33(1), 45-52.
  • Schottelius M, Rau F, Reubi JC, Schwaiger M, Wester HJ. Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogs by variation of peptide net charge and carbohydration chemistry. Bioconj. Chem. 2005, 16(2), 429-437.
  • Schottelius M, Reubi JC, Schwaiger M, Wester HJ. N-terminal sugar conjugation and C-terminal Thr-for-Thr(ol) exchange in radioiodinated Tyr3-octreotide: effect on cellular ligand trafficking in vitro and tumor accumulation in vivo. J. Med. Chem. 2005, 48(8), 2778-2798.
  • Poethko T, Schottelius M, Thumshirn G, Herz M, Haubner R, Henriksen G, Kessler H, Schwaiger M, Wester HJ. Chemoselective pre-conjugate radiohalogenation of unprotected mono- and multimeric peptides via oxime formation. Radiochim. Acta 2004, 92 (4-6), 317-328.
  • Henriksen G, Schottelius M, Poethko T, Hauser A, Wolf I, Schwaiger M, Wester HJ. Proof of principle for the use of 11C-labelled peptides in tumor diagnosis with PET. Eur. J. Nucl. Med. Mol. Imaging, 2004, 31(12), 1653-1657.
  • Wester HJ, Schottelius M, Poethko T, Bruus-Jensen K, Schwaiger M. Radiolabelled carbohydrated somatostatin analogs: a brief review of the current status. Cancer Biother. Radiopharm., 2004, 19(2), 231-244.
  • Poethko T, Schottelius M, Thumshirn G, Hersel U, Herz M, Henriksen G, Kessler H, Schwaiger M, Wester HJ. Two-step methodology for high-yield routine radiohalogenation of peptides: 18F-labelled RGD- and octreotide analogs. J. Nucl. Med., 2004, 45(5), 892-902.
  • Schottelius M, Poethko T, Herz M, Kessler H, Schwaiger M, Wester HJ. First 18F-labelled tracer suitable for routine clinical imaging of sst-receptor expressing tumors using positron emission tomography. Clin. Cancer Res. 2004, 10(11), 3593-3606.
  • Schottelius M, Schwaiger M, Wester HJ. Rapid and high-yield solution phase synthesis of DOTA-Tyr3-octreotide and DOTA-Tyr3-octreotate using unprotected DOTA. Tetrahedron Lett. 2003, 44 (11), 2393 – 2396.
  • Vaidyanathan G, Friedman HS, Schottelius M, Wester HJ, Zalutsky MR. Specific and high-level targeting of radiolabeled octreotide analogues to human medulloblastoma xenografts. Clin. Cancer Res. 2003, 9(5), 1868-1876.
  • Wester HJ, Schottelius M, Scheidhauer K, Meisetschläger G, Herz M, Rau F, Reubi JC, Kimmich T, Arnold W, Schwaiger M. PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide. Eur. J. Nucl. Med. Mol. Imaging 2003, 30(1), 117-122.
  • Schottelius M, Wester HJ, Reubi JC, Senekowitsch-Schmidtke R, Schwaiger M. Improvement of Pharmacokinetics of radioiodinated Tyr3-octreotide by Conjugation with Carbohydrates. Bioconj. Chem. 2002, 13(5), 1021-1030.
  • Wester HJ, Schottelius M, Scheidhauer K, Reubi JC, Wolf I, Schwaiger M. Comparison of radioiodinated TOC, TOCA and Mtr-TOCA: the effect of carbohydration on the pharmacokinetics. Eur. J. Nucl. Med. Mol. Imaging 2002, 29(1), 28-38.

Buchartikel

  • Schottelius M, “Peptide Radiopharmaceuticals”, in: Munich Molecular Imaging Handbook Series, Vol 1. Pharmaceutical Radiochemistry (I), Wester HJ (editor); ISBN 978-3-9813523-0-6
  • Auernheimer J, Schottelius M, Wester HJ, 2008, “Carbohydration of radiolabeled peptides“, In: Recent Advances of Bioconjugation Chemistry in Molecular Imaging, Chen X (editor); ISBN: 978-81-308-0210-7
  • Dijkgraaf I, Schottelius M, Wester HJ, 2008. “F-18 labeling of peptides and proteins”. In: Recent Advances of Bioconjugation Chemistry in Molecular Imaging, Chen X (editor); ISBN: 978-81-308-0210-7
  • Dijkgraaf I, Wester HJ, 2008, “Peptides, Multimers and Polymers”, In: Handbook of Experimental Pharmacology, Molecular Imaging II; W. Semmler, M.Schwaiger (editors), p61-92, Springer Verlag, ISBN 978-3-540-77449-5
  • Wester HJ, Schottelius M, 2007, „Radiopharmaka für die nukleare Onkologie“, in: Nuklearmedizinische Onkologie. BJ. Krause, A. Buck, M. Schwaiger (editors), p87-106, Verlagsgruppe Hüthig Jehle Rehm, ISBN 978-3-609-76308-8
  • Wester HJ, Schottelius M, 2006, “Fluorine-18 labeling of peptides”, In: PET Chemistry, The driving force in Molecular Imaging. PA Schubiger, L.Lehmann, M.Wiebe (editors), p79-112, Springer Verlag, ISBN 13-978-3-540-32623-6